Vigabatrin for refractory partial epilepsy (Q24201569)

31 October 2023

Melissa J Maguire

series ordinal

2

author given names

Melissa J

author last names

Maguire

1 reference

31 October 2023

Jane L Hutton

series ordinal

3

author given names

Jane L

author last names

Hutton

1 reference

31 October 2023

Anthony G Marson

series ordinal

4

author given names

Anthony G

author last names

Marson

1 reference

Cochrane Database of Systematic Reviews

31 October 2023

publication date

31 January 2013

0 references

published in

0 references

cites work

Dose-Response Study of Vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

Effects of vigabatrin on partial seizures and cognitive function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

Double-blind, placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug-resistant epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

Vigabatrin in the treatment of epilepsy: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

Vigabatrin withdrawal randomized study in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

Influence of vigabatrin on cognitive performances and behaviour in patients with drug-resistant epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

Open, double-blind and long-term study of vigabatrin in chronic epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

Vigabatrin: rational treatment for chronic epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

Remission of epilepsy: results from the National General Practice Study of Epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

Severe persistent visual field constriction associated with vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

Treatment of infantile spasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

New antiepileptic drugs: a systematic review of their efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

The legacy of vigabatrin in a regional epilepsy clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

Epidemiology of the epilepsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

Treatment of pediatric epilepsy: expert opinion, 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

Double-blind study of vigabatrin in the treatment of drug-resistant epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

7 January 2021

gamma-Vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

7 January 2021

A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

7 January 2021

Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

7 January 2021

Neuropsychological outcomes in randomized controlled trials of antiepileptic drugs: a systematic review of methodology and reporting standards

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

7 January 2021

Once-daily versus twice-daily vigabatrin: is there a difference? The results of a double-blind pilot study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

7 January 2021

Vigabatrin and epilepsy: lessons learned

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

7 January 2021

A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Vigabatrin Protocol 024 Investigative Cohort

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007302.PUB2

7 January 2021